<div id="readability-page-1"><div><p>Just because a business does not make any money, does not mean that the stock will go down.   For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery.   But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.</p><p> So, the natural question for <strong>Design Therapeutics</strong> (NASDAQ:DSGN) shareholders is whether they should be concerned by its rate of cash burn.   In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'.  The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'. </p><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p><h2> Does Design Therapeutics Have A Long Cash Runway? </h2><p> A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate.   In September 2025, Design Therapeutics had US$206m in cash, and was debt-free.   Looking at the last year, the company burnt through US$52m.   Therefore, from September 2025 it had 3.9 years of cash runway.     A runway of this length affords the company the time and space it needs to develop the business.    The image below shows how its cash balance has been changing over the last few years. </p><figure><img height="1052" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/625814292-debt-equity-history-analysis-1-dark-2/1764092674503?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1642" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/625814292-debt-equity-history-analysis-1-dark-2/1764092674503"/><figcaption>NasdaqGS:DSGN Debt to Equity History November 25th 2025</figcaption></figure><p><span> See our latest analysis for Design Therapeutics </span></p> <h2> How Is Design Therapeutics' Cash Burn Changing Over Time? </h2><p> Because Design Therapeutics isn't currently generating revenue, we consider it an early-stage business.  So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time.     Over the last year its cash burn actually increased by 13%, which suggests that management are increasing investment in future growth, but not too quickly.  That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway.    Clearly, however, the crucial factor is whether the company will grow its business going forward.  For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. </p> <h2> How Easily Can Design Therapeutics Raise Cash? </h2><p> Given its cash burn trajectory, Design Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway.    Companies can raise capital through either debt or equity.  Many companies end up issuing new shares to fund future growth.  By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). </p><p> Design Therapeutics' cash burn of US$52m is about 11% of its US$476m market capitalisation.    As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.  </p><h2> So, Should We Worry About Design Therapeutics' Cash Burn? </h2><p> It may already be apparent to you that we're relatively comfortable with the way Design Therapeutics is burning through its cash.  In particular, we think its cash runway stands out as evidence that the company is well on top of its spending.   While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure.     After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term.     Separately, we looked at different risks affecting the company and spotted <strong>4 warning signs for Design Therapeutics</strong> (of which 2 are a bit concerning!) you should know about.   </p><p>If you would prefer to check out another company with better fundamentals, then do not miss this <strong>free</strong> list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.</p></div></div>

DSGN

<p>Design Therapeutics (NASDAQ:DSGN) has a cash runway of 3.9 years with US$206m in cash and no debt as of September 2025. The company burned through US$52m last year, a 13% increase, indicating investment in growth. Despite the cash burn, the company is well-positioned to raise more funds if needed, with its cash burn representing 11% of its US$476m market cap. Overall, the company is managing its cash effectively, though there are some risks to be aware of.</p>

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth